Please upgrade your browser.
The phosphatidylinositol 3-kinase (PI3K) signaling axis impacts on cancer cell growth, survival, motility, and metabolism. This pathway is activated by several different mechanisms in cancers, including somatic mutation and amplification of genes encoding key components.
Merit Awards recognize the work of oncology fellows who are first authors on outstanding Symposium abstracts. The following fellows have received Merit Awards for their research. Edwin Jason Abel, MD M. D. Anderson Cancer Center Does targeted therapy result in reliable and meaningful primary tumor downstaging in patients with metastatic renal cell carcinoma? (Abstract 318) Renal Cell Cancer Oral Abstract Session C
Blacks with renal cell cancer (RCC) have lower survival rates than whites. While comorbidities, socioeconomic factors, and access to healthcare are suggested to contribute to differences in survival, the effects of race on histology and stage of the RCC have not been studied. We analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database to evaluate the influence of race on histology and stage of RCC.
Frontline sunitinib has been shown to produce a high response rate (RR), and improved progression-free survival (PFS) and overall survival (OS) in patients (pts) with clear cell RCC (ccRCC). Retrospective data suggest sunitinib may be effective in papillary and chromophobe RCC.
The KCA's Facebook Challenge encourages people to become members of the organization's Facebook Fan Page, and then invite others to join. According to Bro, "This helps our charity to easily disseminate information about cutting-edge kidney cancer therapies to patients..."
Dr. Oleg Loran treats kidney cancer, but he doesn't have much to offer his patients. They have a 60% chance of surviving five years if the disease is caught early, but more than a third are diagnosed after the cancer is well advanced, when their chances of reaching the five-year mark drop as low as 11%.
Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer
Although Renal Cell Cancer (RCC) is known to be immunogenic, clinical efficacy of various immunotherapeutic approaches remains unsatisfactory.
Dr. Davidson is testing a new approach to treatment of HHT. He's using the cancer drug Avastin in low doses in both injection and spray forms to stop the nosebleeds.
|Powered by NeonCRM|